Excision BioTherapeutics, Inc., a clinical-stage biotechnology company, announced that the California Institute for Regenerative Medicine (CIRM) has awarded Excision a $6.85 million grant to support the clinical development of the EBT-101 programme for human immunodeficiency virus type 1 (HIV-1).
Daniel Dornbusch, chief executive officer of Excision, commented,
